Zobrazeno 1 - 10
of 201
pro vyhledávání: ''
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
Katherine E. Miller, Kevin A. Cassady, Justin C. Roth, Jennifer Clements, Kathleen M. Schieffer, Kristen Leraas, Anthony R. Miller, Nripesh Prasad, Jianmei W. Leavenworth, Inmaculada B. Aban, Richard J. Whitley, G. Yancey Gillespie, Elaine R. Mardis, James M. Markert
Publikováno v:
Clin Cancer Res
Purpose: Previously, clinical trials of experimental virotherapy for recurrent glioblastoma multiforme (GBM) demonstrated that inoculation with a conditionally replication–competent Δγ134.5 oncolytic herpes simplex virus (oHSV), G207, was safe. F
Autor:
Manish R. Patel, Peng He, Antoinette R. Tan, Anita Scheuber, Shannon Marshall, Anton I. Rosenbaum, Kemal Balic, Erika Hamilton, Mark D. Pegram, Mayukh Das, Meina Liang, Anna Maria Storniolo
Publikováno v:
Molecular Cancer Therapeutics. 20:1442-1453
MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in subdomains 2 and 4 of the HER2 ecto-domain, with site-specific conjugation to a tubulysin-based microtubule inhibitor payload. MEDI4276 demonstrates enhanced cell
Autor:
Martin H. Voss, Ed Reznik, Diego Chowell, Renzo G. DiNatale, Yasuhiro Funahashi, Pallavi Sachdev, Chung-Han Lee, Chirag Krishna, Mark Lee, Kate Weiss, Yukinori Minoshima, Darren R. Feldman, Robert J. Motzer, Doug Hoen, A. Ari Hakimi, Lynda Vuong, Samuel Murray, Luc G. T. Morris, Timothy A. Chan, Ritesh Kotecha, Junji Matsui, Maria I. Carlo, Kenichi Nomoto, Yusuke Adachi, Vladimir Makarov, Cristina Valero
Publikováno v:
Mol Cancer Res
Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have improved th
Autor:
Adrian Wiestner, Michael A. E. Andersen, Carsten Utoft Niemann, Inhye E. Ahn, Mathias H. Torp, Kathrine Aarup, Xin Tian, Christina Westmose Yde, Christian Brieghel
Publikováno v:
Clin Cancer Res
Purpose: TP53 aberration (TP53 mutation and/or 17p deletion) is the most important predictive marker in chronic lymphocytic leukemia (CLL). Although each TP53 aberration is considered an equal prognosticator, the prognostic value of carrying isolated
Publikováno v:
Cancer Res
Women with a history of ductal carcinoma in situ (DCIS) have an elevated risk of a subsequent invasive breast cancer, but there are few established potentially modifiable factors known to lower this risk. Bisphosphonates are a commonly used treatment
Autor:
Manisha Palta, Kent J. Weinhold, Brian G. Czito, David M. Brizel, John S. Yi, April K.S. Salama, Christel Rushing, Douglas S. Tyler, Brent A. Hanks, Georgia M. Beasley, David S. Yoo, Paul J. Mosca, Kristen N. Linney, M. Angelica Selim, Chelsae Dumbauld, Katelyn N. Steadman, Walter T. Lee
Publikováno v:
Clin Cancer Res
Purpose:In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma.Patients and Methods:Twenty-
Autor:
Jessica Hoare, Katrina Purtell, Elizabeth A. Sugar, Raka Bhattacharya, Arsen Osipov, Daniel A. Laheru, Katherine M. Bever, Rose Parkinson, Beth Onner, Matthew J. Weiss, Jin He, Ding Ding, Qingfeng Zhu, Elizabeth M. Jaffee, Guanglan Mo, Elizabeth D. Thompson, Amy Hacker-Prietz, Victoria M. Kim, Martin A. Makary, Hongyan Cai, Barish H. Edil, Richard D. Schulick, Robert A. Anders, John L. Cameron, Joseph M. Herman, Lindsey Manos, Nilofer S. Azad, Christopher L. Wolfgang, Dung T. Le, Dwayne L. Thomas, Jennifer N. Durham, Kevin C. Soares, Carol Judkins, Alex B. Blair, Ana De Jesus-Acosta, Sara Solt, Lei Zheng
Publikováno v:
Clin Cancer Res
Purpose: Immunotherapy is currently ineffective for nearly all pancreatic ductal adenocarcinomas (PDAC), largely due to its tumor microenvironment (TME) that lacks antigen-experienced T effector cells (Teff). Vaccine-based immunotherapies are known t
Autor:
Guanghui Gao, Zhe-Hai Wang, Jifeng Feng, Meijuan Huang, Xinmin Yu, Zhihua Liu, Caicun Zhou, Lihong Wu, Yina Wang, Ying Cheng, Jun Zhao, Yuan Chen, Zhiyong Ma, Weixia Li, Xiaoyan Lin, Shengxiang Ren, Kangsheng Gu, R. Guo, Jun Zhang, Quan Ren Wang, Xinfeng Yang, Gongyan Chen, Yu Yao, Jianxing He, Jianhua Chen, Jianhua Shi
Publikováno v:
Clinical Cancer Research. 27:1296-1304
Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T cells and reducing recruitment of tumor-associated macrophages. We hereby
Autor:
Xiao-Ou Shu, Ingrid A. Mayer, Wei Zheng, Christina E. Bailey, Jennifer A. Pietenpol, Fei Wang
Publikováno v:
Cancer Research. 81:1163-1170
It is unclear whether racial/ethnic disparities in triple-negative breast cancer (TNBC) mortality remain after accounting for clinical characteristics, treatment, and access-to-care–related factors. In this study, women with a primary diagnosis of